{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:31:18Z","timestamp":1790613078757,"version":"4.1.0"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T00:00:00Z","timestamp":1667520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100010643","name":"Cidara Therapeutics","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010643","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Rezafungin EUCAST MIC testing has been associated with notable inter-laboratory variation, which prevented ECOFF setting for C. albicans. We assessed in vitro susceptibility and reproducibility for a modified EUCAST methodology and established associated wild-type upper limits (WT-ULs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>MICs against 150 clinical Candida isolates (six species), molecularly characterized fks mutants (n\u200a=\u200a13), and QC strains (n\u200a=\u200a6) were determined at six laboratories according to E.Def 7.3 but using Tween 20 supplemented medium. WT-ULs were determined using the derivatization method, the ECOFFinder programme and visual inspection. Consensus WT-ULs were determined.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The laboratory- and species-specific MIC distributions were Gaussian with &amp;gt;99.5% MICs within four 2-fold dilutions except for C. parapsilosis (92.8%). The following consensus WT-UL were determined: C. albicans 0.008\u2005mg\/L; C. dubliniensis and C. glabrata 0.016\u2005mg\/L; C. krusei and C. tropicalis 0.03\u2005mg\/L; and C. parapsilosis 4\u2005mg\/L. Adopting these WT-UL, six clinical isolates were non-wild-type, five of which harboured Fks alterations. For 11\/13 mutants, all 670 MICs were categorized as non-wild-type whereas MICs for C. glabrata Fks2 D666Y and C. tropicalis Fks1 R656R\/G overlapped with the corresponding wild-type distributions. Repeat testing of six reference strains yielded 98.3%\u2013100% of MICs within three 2-fold dilutions except for C. albicans CNM-CL-F8555 (96%) and C. parapsilosis ATCC 22019 (93.3%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The modified EUCAST method significantly improved inter-laboratory variation, identified wild-type populations and allowed perfect separation of wild-type and fks mutants except for two isolates harbouring weak mutations. These consensus WT-UL have been accepted as ECOFFs and will be used for rezafungin breakpoint setting.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkac373","type":"journal-article","created":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T05:35:06Z","timestamp":1667540106000},"page":"185-195","source":"Crossref","is-referenced-by-count":13,"title":["Multicentre validation of a modified EUCAST MIC testing method and development of associated epidemiologic cut-off (ECOFF) values for rezafungin"],"prefix":"10.1093","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4747-0144","authenticated-orcid":false,"given":"Maiken Cavling","family":"Arendrup","sequence":"first","affiliation":[{"name":"Unit of Mycology, Statens Serum Institut , Copenhagen , Denmark"},{"name":"Department of Clinical Microbiology, Rigshospitalet , Copenhagen , Denmark"},{"name":"Department of Clinical Medicine, University of Copenhagen , Copenhagen , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9807-6764","authenticated-orcid":false,"given":"Sevtap","family":"Arikan-Akdagli","sequence":"additional","affiliation":[{"name":"Unit of Mycology, Department of Medical Microbiology, Hacettepe University Medical School , Ankara , Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0126-1782","authenticated-orcid":false,"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[{"name":"JMI Laboratories , North Liberty, IA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7901-8355","authenticated-orcid":false,"given":"Jesus","family":"Guinea","sequence":"additional","affiliation":[{"name":"Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Mara\u00f1\u00f3n , Madrid , Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n , Madrid , Spain"},{"name":"CIBER Enfermedades Respiratorias-CIBERES (CB06\/06\/0058) , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8145-0828","authenticated-orcid":false,"given":"Jeffrey B","family":"Locke","sequence":"additional","affiliation":[{"name":"Cidara Therapeutics Inc. , San Diego, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8869-1509","authenticated-orcid":false,"given":"Joseph","family":"Meletiadis","sequence":"additional","affiliation":[{"name":"Clinical Microbiology Laboratory, Attikon University Hospital, National and Kapodistrian University of Athens , Athens , Greece"},{"name":"Department of Medical Microbiology and Infectious Diseases, Erasmus MC , Rotterdam , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1581-0845","authenticated-orcid":false,"given":"Oscar","family":"Zaragoza","sequence":"additional","affiliation":[{"name":"Mycology Reference Laboratory, National Centre for Microbiology, Health Institute Carlos III , Majadahonda, Madrid , Spain"},{"name":"Center for Biomedical Research in Network in Infectious Diseases (CIBERINFEC-CB21\/13\/00105), Instituto de Salud Carlos III , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,11,4]]},"reference":[{"key":"2023010801143874900_dkac373-B1","doi-asserted-by":"crossref","first-page":"6872","DOI":"10.1128\/AAC.00701-16","article-title":"Preclinical evaluation of the stability, safety, and efficacy of CD101, a novel echinocandin","volume":"60","author":"Ong","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2023010801143874900_dkac373-B2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.01541-16","article-title":"Structure-activity relationships of a series of echinocandins and the discovery of CD101, a highly stable and soluble echinocandin with distinctive pharmacokinetic properties","volume":"61","author":"James","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023010801143874900_dkac373-B3","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00758-17","article-title":"Pharmacological basis of CD101 efficacy: exposure shape matters","volume":"61","author":"Lakota","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023010801143874900_dkac373-B4","article-title":"Safety and pharmacokinetics of CD101 IV, a novel echinocandin, in healthy adults","volume":"61","author":"Sandison","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2023010801143874900_dkac373-B5","doi-asserted-by":"crossref","first-page":"e3647","DOI":"10.1093\/cid\/ciaa1380","article-title":"Rezafungin versus caspofungin in a phase 2, randomized, double-blind study for the treatment of candidemia and invasive candidiasis: the STRIVE trial","volume":"73","author":"Thompson","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023010801143874900_dkac373-B6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.02438-19","article-title":"Rezafungin in vitro activity against contemporary Nordic clinical Candida isolates and Candida auris determined by the EUCAST reference method","volume":"64","author":"Helleberg","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2023010801143874900_dkac373-B7","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1093\/jac\/dkx008","article-title":"In vitro activity of the novel echinocandin CD101 at pH 7 and 4 against Candida spp. Isolates from patients with vulvovaginal candidiasis","volume":"72","author":"Boikov","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2023010801143874900_dkac373-B8","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1128\/AAC.06369-11","article-title":"Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations","volume":"56","author":"Arendrup","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2023010801143874900_dkac373-B9","doi-asserted-by":"crossref","DOI":"10.1128\/jcm.02449-21","article-title":"Evaluation of rezafungin provisional CLSI clinical breakpoints and epidemiological cutoff values tested against a Worldwide Collection of Contemporaneous Invasive Fungal Isolates (2019 to 2020)","volume":"60","author":"Carvalhaes","year":"2022","journal-title":"J Clin Microbiol"},{"key":"2023010801143874900_dkac373-B10","author":"CLSI"},{"key":"2023010801143874900_dkac373-B11","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.cmi.2018.02.021","article-title":"Multicentre determination of rezafungin (CD101) susceptibility of Candida species by the EUCAST method","volume":"24","author":"Arendrup","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2023010801143874900_dkac373-B12","author":"European Committee on Antimicrobial Susceptibility Testing"},{"key":"2023010801143874900_dkac373-B13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.00659-19","article-title":"EUCAST Reference testing of rezafungin susceptibility and impact of choice of plastic plates","volume":"63","author":"Arendrup","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2023010801143874900_dkac373-B14","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1093\/jac\/dkab088","article-title":"ISO Standard 20776-1 or serial 2-fold dilution for antifungal susceptibility plate preparation: that is the question!","volume":"76","author":"Arendrup","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2023010801143874900_dkac373-B15","doi-asserted-by":"crossref","first-page":"e01760-18","DOI":"10.1128\/AAC.01760-18","article-title":"Effects of microplate type and broth additives on microdilution MIC susceptibility assays","volume":"63","author":"Kavanagh","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2023010801143874900_dkac373-B16","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1128\/AAC.01513-07","article-title":"Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing","volume":"52","author":"Arhin","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2023010801143874900_dkac373-B17","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.diagmicrobio.2012.08.025","article-title":"Use of a surfactant (polysorbate 80) to improve MIC susceptibility testing results for polymyxin B and colistin","volume":"74","author":"Sader","year":"2012","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2023010801143874900_dkac373-B18","first-page":"S87","article-title":"Development and validation of a modified EUCAST yeast broth microdilution MIC method for rezafungin to mitigate nonspecific binding through incorporation of Tween 20","author":"Zuill","year":"2021","journal-title":"Eur Congr Clin Microbiol Infect Dis"},{"key":"2023010801143874900_dkac373-B19","doi-asserted-by":"crossref","first-page":"571.e1","DOI":"10.1016\/j.cmi.2016.01.017","article-title":"EUCAST technical note on isavuconazole breakpoints for Aspergillus, itraconazole breakpoints for Candida and updates for the antifungal susceptibility testing method documents","volume":"22","author":"Arendrup","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"2023010801143874900_dkac373-B20","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1128\/JCM.02071-10","article-title":"Candida palmioleophila: characterization of a previously overlooked pathogen and its unique susceptibility profile in comparison with five related species","volume":"49","author":"Jensen","year":"2011","journal-title":"J Clin Microbiol"},{"key":"2023010801143874900_dkac373-B21","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1469-0691.2006.01377.x","article-title":"Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values","volume":"12","author":"Turnidge","year":"2006","journal-title":"Clin Microbiol Infect"},{"key":"2023010801143874900_dkac373-B22","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02372-16","article-title":"In vitro antifungal susceptibility testing of Candida isolates with the EUCAST methodology, a new method for ECOFF determination","volume":"61","author":"Meletiadis","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023010801143874900_dkac373-B23","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.1128\/AAC.01519-13","article-title":"Interlaboratory variability of caspofungin MICs for Candida spp. using CLSI and EUCAST methods: should the clinical laboratory be testing this agent?","volume":"57","author":"Espinel-Ingroff","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2023010801143874900_dkac373-B24","doi-asserted-by":"crossref","first-page":"ofab431","DOI":"10.1093\/ofid\/ofab431","article-title":"Expanded access use of rezafungin for salvage therapy of invasive Candida glabrata infection: a case report","volume":"8","author":"Adeel","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2023010801143874900_dkac373-B25","doi-asserted-by":"crossref","first-page":"e02154-17","DOI":"10.1128\/AAC.02154-17","article-title":"Pharmacodynamics of a long-acting echinocandin, CD101, in a neutropenic invasive-candidiasis murine model using an extended-interval dosing design","volume":"62","author":"Lepak","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2023010801143874900_dkac373-B26","doi-asserted-by":"crossref","first-page":"e10080","DOI":"10.1371\/journal.pone.0010080","article-title":"Development of azole resistance in Aspergillus fumigatus during azole therapy associated with change in virulence","volume":"5","author":"Arendrup","year":"2010","journal-title":"PLoS ONE"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/1\/185\/48444484\/dkac373.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/1\/185\/48444484\/dkac373.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,8]],"date-time":"2023-01-08T01:15:05Z","timestamp":1673140505000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/78\/1\/185\/6795450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,4]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,11,4]]},"published-print":{"date-parts":[[2023,1,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkac373","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,1,5]]},"published":{"date-parts":[[2022,11,4]]}}}